Basit öğe kaydını göster

dc.contributor.authorAbu Al Magd, Megahed
dc.contributor.authorKaradeniz, Sehnaz
dc.contributor.authorMeriden, Terry
dc.contributor.authorMisha'l, Aly A.
dc.contributor.authorPozzilli, Paolo
dc.contributor.authorShera, Samad
dc.contributor.authorThomas, Abraham
dc.contributor.authorBahijri, Suhad
dc.contributor.authorTuomilehto, Jaakko
dc.contributor.authorYilmaz, Temel
dc.contributor.authorUmpierrez, Guillermo E.
dc.contributor.authorIbrahim, Mahmoud
dc.contributor.authorAnnabi, Firas A.
dc.contributor.authorAssaad-Khalil, Samir
dc.contributor.authorBa-Essa, Ebtesam M.
dc.contributor.authorFahdil, Ibtihal
dc.date.accessioned2021-03-04T10:57:23Z
dc.date.available2021-03-04T10:57:23Z
dc.date.issued2015
dc.identifier.citationIbrahim M., Abu Al Magd M., Annabi F. A. , Assaad-Khalil S., Ba-Essa E. M. , Fahdil I., Karadeniz S., Meriden T., Misha'l A. A. , Pozzilli P., et al., "Recommendations for management of diabetes during Ramadan: update 2015", BMJ OPEN DIABETES RESEARCH & CARE, cilt.3, sa.1, 2015
dc.identifier.otherav_6fd65914-2813-473c-a672-677c86bb7819
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/77145
dc.identifier.urihttps://doi.org/10.1136/bmjdrc-2015-000108
dc.description.abstractSince the first ADA working group report on the recommendations for management of diabetes during Ramadan in 2005 and our update in 2010, we received many inquiries asking for regular updates on information regarding education, nutritional habits and new oral and injectable agents that may be useful for the management of patients with diabetes during Ramadan. Patients can be stratified into their risk of hypoglycemia and/or complications prior to the start of the fasting period of Ramadan. Those at high risk of hypoglycemia and with multiple diabetic complications should be advised against prolonged fasting. Even in the lower hypoglycemia risk group, adverse effects may still occur. In order to minimize adverse side effects during fasting in patients with diabetes and improve or maintain glucose control, education and discussion of glucose monitoring and treatment regimens should occur several weeks prior to Ramadan. Agents such as metformin,
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.titleRecommendations for management of diabetes during Ramadan: update 2015
dc.typeMakale
dc.relation.journalBMJ OPEN DIABETES RESEARCH & CARE
dc.contributor.departmentEDC , ,
dc.identifier.volume3
dc.identifier.issue1
dc.contributor.firstauthorID220555


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster